# NICOLAS (NCT02434081)

> NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02434081
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: ETOP IBCSG Partners Foundation
- Conditions: Non-small Cell Lung Cancer Stage III
- Interventions: Nivolumab
- Enrollment: 94
- Primary outcome: Grade ≥3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy

## Indexed commentary on NICOLAS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nicolas-nct02434081